Gitnux/Report 2026

Tasmanian Poppy Industry Statistics

9Statistics
7Sources
3Sections
7mRead
How this report is researched
01Editorial Scope

An editor sets the topic, the inclusion criteria, and the evaluation framework before research starts.

02Source Research

AI search agents locate sources and extract each figure together with the document it came from.

Read our full methodology →

Search agents attach provenance to every extracted figure.

Next review: within 28 days

01 Industry overview

The tasmanian poppy industry at a glance

Tasmania’s pharmaceutical poppy industry harvested 9,710 hectares in the 2025–26 season, supplying almost half of global demand for licit alkaloid material and remaining a tightly regulated, export-oriented sector.

9,710[3]
Hectares harvested, 2025–26
389[3]
Active licences, 2025–26
Almost 50%[3]
Share of global licit demand
$33.5M+[3]
Grower payments, 2024–25
Market size
The latest public estimate places the Tasmanian poppy industry’s farm-gate value at approximately $30 million–$50 million in recent years. A separate industry submission reports more than $33.5 million paid to growers for over 8,600 hectares of contracted crop in 2024–25.[2][3]
Market share & regions
Tasmania is identified by the Tasmanian Government as the world’s largest producer of licit alkaloid material and supplies almost half of global demand. Public sources reviewed do not provide a current numerical breakdown of market share by destination region.[3]
Segmentation
Production is segmented by the pharmaceutical alkaloids extracted from different poppy varieties, including morphine, thebaine and codeine. Industry sources also identify specialised varieties such as thebaine-only, codeine-only and noscapine crops.[3][5][4]
Key players & concentration
The Tasmanian Government lists two licensed processors: Extractas Bioscience, trading as Tasmanian Alkaloids, and Sun Pharmaceuticals. This indicates a highly concentrated processing structure, with growers required to hold a processor contract before applying for a cultivation licence.[3]
Pricing
Extractas Bioscience announced a 15% increase in crop payments for the 2026–27 crop: a 5% increase to the regular payment line plus a temporary 10% supplement linked to higher fuel and agricultural-input costs. Public sources do not disclose absolute per-hectare or per-tonne prices.[4]
Trends, drivers & challenges
Harvested area increased from 4,629 hectares in 2023–24 to 9,710 hectares in 2025–26, reflecting stronger demand and renewed planting. Drivers include demand for pharmaceutical ingredients used in pain medicines and emerging demand associated with GLP-1 weight-loss treatments, while growers face higher input costs, crop-performance variability and restrictions on some breeding technologies.[3][1]
Consumer behavior & competition
Demand is business-to-business rather than consumer-facing: Tasmanian alkaloids enter controlled pharmaceutical supply chains. Competition is concentrated between two licensed processors, while market demand has recently been supported by pharmaceutical requirements for opioid ingredients and ingredients linked to GLP-1 medicines.[3][1]
M&A
In 2026, Siegfried acquired Extractas Bioscience, Tasmania’s largest poppy processor, from SK Capital Partners. The transaction changed ownership of a major processor but did not alter the government’s publicly listed total of two licensed Tasmanian processors.[5][4]
Regulation
Growing, manufacturing, selling or possessing alkaloid poppies in Tasmania requires a licence, and growers must also have a valid contract with a licensed processor. The Poppy Advisory and Control Board regulates cultivation, including active licences and notices to grow for specific properties and crops.[3][2]
Latest news
The most significant 2026 development was Siegfried’s acquisition of Extractas Bioscience. The 2026–27 season also brought a reported 15% increase in Extractas crop payments, as the industry responded to higher input costs and improved pharmaceutical demand.[4]

03 Statistics

Market Intelligence

Market size, volume and shipments in the tasmanian poppy industry

  • Approximately 100 tonnes of raw pharmaceutical ingredients were extracted annually from Extractas Bioscience’s Tasmanian poppy production and shipped to global wholesalers and drug manufacturers.[1]
  • A$30–50 million was the Tasmanian poppy industry’s farm-gate value in recent years, covering licensed pharmaceutical alkaloid-poppy production in Tasmania; reported in November 2025.[2]

04 Statistics

Operating Benchmarks

Core operating metrics in the tasmanian poppy industry

  • 9,710 hectares were harvested in Tasmania in the 2025–26 season; hectares are the physical harvested-area measure used for pharmaceutical poppy cultivation.[3]
  • 389 active cultivation licences covered Tasmania’s pharmaceutical poppy industry in the 2025–26 growing season; the measure counts active licences, not licences issued during the season.[3]
  • 7,564 hectares were sown in Tasmania in 2024–25, up from 5,033 hectares in 2023–24; hectares are the industry’s planted-area measure.[3]

05 Statistics

Pricing & Finance

Prices and price indices for tasmanian poppy

  • The contracted price for noscapine-producing poppy varieties increased 15% for the 2025 season, following a 6% increase in 2024; this is a product-specific grower payment movement.[4]
  • The contracted price for thebaine-producing poppy varieties increased 3% for the 2025 season, following a 6% increase in 2024; this is a product-specific grower payment movement.[4]
  • A$2,000 per tonne was the minimum contracted price offered to Tasmanian poppy growers for the 2025 season, up from A$1,100 per tonne; this is a processor contract price for alkaloid poppy raw material.[4]
  • Returns to Tasmanian opium-poppy growers fell nearly 20% over the five years to 2023, an industry-wide movement in grower returns rather than a retail selling-price index.[1]
Reference

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
Samuel Norberg. (2026, November 20). Tasmanian Poppy Industry Statistics. Gitnux. https://gitnux.org/tasmanian-poppy-industry-statistics
MLA
Samuel Norberg. "Tasmanian Poppy Industry Statistics." Gitnux, 20 Nov 2026, https://gitnux.org/tasmanian-poppy-industry-statistics.
Chicago
Samuel Norberg. 2026. "Tasmanian Poppy Industry Statistics." Gitnux. https://gitnux.org/tasmanian-poppy-industry-statistics.